ClinicalTrials.gg
RecruitingNCT07178925ReLapsUpdated Oct 27, 2026

Follow-up Cohort of Patients With Antiphospholipid Syndrome

An observational study in Antiphospholipid Syndrome (APS), sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University Hospital, Rouen · Observational

How we know

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years 1 month later.
Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
200
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Antiphospholipid Syndrome with a site in France — 11 open to participants now, 11 under way, 1 of them phase 3. Antiphospholipid Syndrome · France.

Planned enrollment
10th of 17
200 · median 310
Started
2019
with 2 others
Observational
17 of 31
5 open now
Primary completion
2027-10
later than 2 of 10 live
Registered
28th of 31
by date
Lead sponsor
2 of 31
University Hospital, Rouen

Among the 31 studies in Antiphospholipid Syndrome with a site in France, this one is the 10th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2019, is one of 17 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 28th registered.

Antiphospholipid Syndrome

121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.

Browse Antiphospholipid Syndrome studies →

Open to participants now

11 of the 31 studies in Antiphospholipid Syndrome with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 38 Antiphospholipid Syndrome studies recruiting now, 14 (37%) set no upper age limit and 19 (50%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Antiphospholipid Syndrome with a site in France, or all of them as a file.
02

Study summary

Antiphospholipid syndrome (APLS) is a rare pathology characterized by the association of thrombotic (arterial, venous) or obstetric clinical manifestations and the persistent presence at least twelve weeks apart of antiphospholipid antibodies (APL). It is also accompanied by accelerated atherosclerosis responsible for an increased incidence of myocardial infarction, peripheral arterial disease and stroke explaining the high cardiovascular morbidity and mortality of these patients. APS can be isolated (primary) or integrated into an autoimmune pathology such as systemic lupus erythematosus (SLE), thus defining secondary APS. Current treatment is based on anticoagulation. Currently, epidemiological data that have evaluated recurrences have estimated a rate of 5% per year. However, these studies are old and due to the significant heterogeneity of patients included in this registry, it seems that these figures are not in agreement with clinical reality.

Furthermore, several new therapeutic developments have emerged in the field of anticoagulation with the marketing of DOACs, making the EUROPHOSPHOLIPIDE data questionable. Currently, there are no clinical studies to justify the use of DOACs in this indication, but several patients have received these drugs due to intolerance or refusal of vitamin K antagonists. The other therapeutic innovation compared to the data from the EUROPHOSPHOLIPIDE cohort is the increasing use of hydroxychloroquine in clinical practice in patients with primary APS. A trial (APLAQUINE) is currently underway in our department which aims to study the endothelial protective effect of this treatment in patients with primary APS.

Read the detailed description

This trial is a retrospective and prospective cohort epidemiological study whose primary objective is to determine the rate of thrombotic recurrence in our center. Secondary objectives are to determine the risk factors associated with recurrence, assess the safety of long-term treatment in this population, and evaluate the overall morbidity and mortality of this rare disease.

A better understanding of thrombotic recurrence is essential to calculate realistic population sizes for future therapeutic trials.

03

Conditions studied

  • Antiphospholipid Syndrome (APS)

Keywords

  • thrombotic recurrence rate
  • risk factors
  • treatment tolerance
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients monitored for Antiphospholipid Syndrome (APLS) in the internal medicine department

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over 18 years of age and under 75 years of age
  • Antiphospholipid syndrome meeting the 2006 Sydney classification

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 75 or over
  • Syndrome not meeting the 2006 Sydney classification
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • OtherStudy of Antiphospholipid Syndrome responding to the Sydney classification of 2006

    The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department, to evaluate the complication rate associated with treatment, to search for risk factors associated with thrombotic recurrence and to define the mortality and morbidity rates of this patient population.

06

What researchers measure

Primary outcomes

  1. Thrombotic recurrence rate

    The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department.

    Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.

Secondary outcomes

  1. Complication rate

    Evaluate the complication rate associated with treatment

    Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.

  2. Risk factors associated

    Look for risk factors associated with thrombotic recurrence

    Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.

  3. Mortality rates

    Evaluate the mortality rates of this patient population

    Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.

  4. Morbidity rates

    Evaluate the morbidity rates of this patient population

    Time frame: Patients will be followed up in consultation every 3 months, 6 months to 1 year, for 5 years, depending on the situation. Follow-ups will not be modified compared to the usual management of the disease.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The data provided will be the property of the sponsor and will be used solely for its own research activities.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2019 (actual). Primary completion is estimated for Oct 2027, 96 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2031 → Oct 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartActual
Oct 16, 2019
Primary completionEst.
Oct 16, 2027was Oct 2026
CompletionEst.
Oct 16, 2032was Oct 2031
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 16, 2026→Oct 16, 2027
Oct 27, 2026
Study completion
Oct 16, 2031→Oct 16, 2032
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Oct 16, 2026→Oct 16, 2027
    Study completion Oct 16, 2031→Oct 16, 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07178925
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Oct 16, 2019
Primary completion
Oct 16, 2027 (estimated)
Completion
Oct 16, 2032 (estimated)
Last update
Oct 27, 2026

Study contacts

Sébastien SM MIRANDA, Doctor
Contact
Sebastien.Miranda@chu-rouen.fr
02 32 88 90 01 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion